Prime Therapeutics shifts to upfront drug pricing model
Summary
Prime Therapeutics, one of the largest pharmacy benefit managers in the US, is shifting toward a model of upfront drug pricing to reduce complexity and address rising patient costs associated with rebates. This move aligns with a broader trend among pharmacy benefit managers advocating for pricing reform, aiming to create a more transparent system that simplifies transactions and mitigates cost concerns for patients.
Analysis
Prime Therapeutics: Prime Therapeutics is one of the largest pharmacy benefit managers operating in the United States. The company is transitioning its drug pricing approach to upfront payments rather than the traditional rebates-based model. This shift directly responds to ongoing criticism that rebate systems contribute to higher out-of-pocket costs for patients. Pricing Reform: Pharmacy benefit managers are moving toward transparent upfront drug pricing models to simplify transactions and address patient cost concerns.
Categories
macropolitics